Literature DB >> 2713698

Repeated haloperidol administration changes basal release of striatal dopamine and subsequent response to haloperidol challenge.

W Zhang1, H Tilson, M K Stachowiak, J S Hong.   

Abstract

The effects of acute or repeated administration of haloperidol on release of dopamine (DA) and homovanillic acid (HVA) from striata of awake rats were studied using a microdialysis probe. A single injection of haloperidol (1 mg/kg, i.p.) produced a time-dependent increase in DA and HVA in the perfusate. Comparative studies in rats anesthetized with 300 mg/kg of chloral hydrate given i.p. found that anesthesia decreased the basal release of DA, but not HVA, and significantly blocked haloperidol-induced increases in DA, while haloperidol-induced increases in HVA were not affected. Studies done in awake rats found that 21 repeated daily injections of haloperidol increased the basal release of DA, but not HVA. Subsequent challenge with haloperidol indicated a significant decrease in responsiveness to haloperidol-induced release of DA, but not HVA, in chronically dosed rats. These data suggest that repeated exposure to haloperidol causes a compensatory increase in extracellular DA release. That these compensatory changes may be associated with the increased therapeutic efficacy or extrapyramidal side effects of neuroleptics following repeated dosing warrants further study.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2713698     DOI: 10.1016/0006-8993(89)90387-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

Review 1.  Effects of chronic neuroleptic treatment on dopamine release: insights from studies using 3-methoxytyramine.

Authors:  M F Egan; S Chrapusta; F Karoum; B K Lipska; R J Wyatt
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.

Authors:  C J Bench; A A Lammertsma; P M Grasby; R J Dolan; S J Warrington; M Boyce; K P Gunn; L Y Brannick; R S Frackowiak
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  Characterization of the in vivo release of dopamine as recorded by different types of intracerebral microdialysis probes.

Authors:  M Santiago; B H Westerink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-10       Impact factor: 3.000

4.  Effects of a single haloperidol application to neonatal and early postnatal rats on the neurotransmitter content in the corpus striatum.

Authors:  R Schwabe; R Thiel; I Chahoud; D Neubert
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

5.  Influence of acute and chronic haloperidol treatment on dopamine metabolism in the rat caudate-putamen, prefrontal cortex and amygdala.

Authors:  E C Essig; I C Kilpatrick
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

6.  Dopaminergic function in rat brain after oral administration of calcium-channel blockers or haloperidol. A microdialysis study.

Authors:  J Reiriz; S Ambrosio; A Cobos; M Ballarín; E Tolosa; N Mahy
Journal:  J Neural Transm Gen Sect       Date:  1994
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.